Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-cash Items (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Non-cash Items for 12 consecutive years, with $1000.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items changed N/A to $1000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $1000.0 for FY2025, N/A changed from the prior year.
  • Non-cash Items for Q4 2025 was $1000.0 at Anika Therapeutics, roughly flat from $1000.0 in the prior quarter.
  • The five-year high for Non-cash Items was $4.7 million in Q3 2021, with the low at $1000.0 in Q2 2025.
  • Average Non-cash Items over 5 years is $574000.0, with a median of $188000.0 recorded in 2023.
  • The sharpest move saw Non-cash Items soared 6922.22% in 2023, then plummeted 99.67% in 2025.
  • Over 5 years, Non-cash Items stood at $975000.0 in 2021, then grew by 7.69% to $1.0 million in 2022, then plummeted by 87.9% to $127000.0 in 2023, then soared by 95.28% to $248000.0 in 2024, then crashed by 99.6% to $1000.0 in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $1000.0, $1000.0, and $248000.0 for Q4 2025, Q2 2025, and Q3 2024 respectively.